CoChat
Sign Up
Cited by 13Thyroid Disorders and TreatmentsThyroid Cancer Diagnosis and TreatmentBlood properties and coagulation

Levothyroxine (LT4) suppression treatment for benign thyroid nodules alters coagulation

Demir, Tevfik, Akinci, Baris, Comlekci, Abdurrahman, Karaoglu, Oguzhan, Ozcan, Mehmet Ali, Yener, Serkan, Yuksel, Faize, Secil, Mustafa +1 more·2009·Clinical Endocrinology
DOI 10.1111/j.1365-2265.2008.03497.x
Open this paper in CoChat — free account

Abstract

Summary: Objective Endogenous hyperthyroidism is associated with altered coagulation. The aim of the present study is to investigate the effect of levothyroxine (LT 4) suppression treatment for benign thyroid nodules on coagulation system. Design Prospective case‐control study. Patients Thirty consecutive euthyroid pre‐menopausal women with nodular goitre disease and 28 healthy controls were included in the study. Measurements Plasma fibrinogen, d‐dimer, von Willebrand factor (vWF), tissue factor (TF), tissue plasminogen activator (tPA), plasminogen activator inhibitor (PAI‐1) and tissue factor pathway inhibitor (TFPI) levels were measured at baseline and after LT 4 suppression therapy. Results Plasma levels of fibrinogen, d‐dimer, vWF, TF and PAI‐1 increased significantly after treatment with LT 4 for 1 year. Serum FT 4 was a significant predictor of increased fibrinogen, vWF and PAI‐1 levels, when the data was controlled for age and BMI. Conclusions Our results suggest that LT 4 suppression therapy for benign thyroid nodules is associated with enhanced coagulation.

Integrity signals

Registry

Crossref · 10.1111/j.1365-2265.2008.03497.x

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Thyrotoxicosis induced by administration of LT4 to healthy volunteers and those with thyroid nodules induces a procoagulant state, associated with increased levels of FVIII, FIX, FX, VWF, fibrinogen D-dimer, and PAI-1 with delayed fibrin clot lysis and a shortening of the APTT, but with an inconsistent impact on clot structure parameters.

    “Thyrotoxicosis induced by administration of LT4 to healthy volunteers and those with thyroid nodules also induces a procoagulant state, associated with increased levels of FVIII, FIX, FX, VWF, fibrinogen D-dimer, and PAI-1 with delayed fibrin clot lysis and a shortening of the APTT, but with an inconsistent impact on clot structure parameters”

    From Pharmacodynamic and Therapeutic Actions of Levothyroxine (2021) · cites this paper as [119]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Demir, T., Akinci, B., Comlekci, A., Karaoglu, O., Ozcan, M. A., Yener, S., Yuksel, F., Secil, M., & Yesil, S.
Affiliations
Dokuz Eylül University (TR)
ORCID
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2009-08-14
Volume
71
Issue
3
Pages
446-450
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
DOI
10.1111/j.1365-2265.2008.03497.x
OpenAlex
W2126317756
Cited by
13
References
41
Citations by year
2022: 2 · 2021: 2 · 2020: 1 · 2018: 2 · 2016: 1 · 2015: 1 · 2012: 2
FWCI
0.48
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Clinical Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Blood properties and coagulation
Keywords
levothyroxine suppression therapy, benign thyroid nodules, nodular goiter, coagulation, fibrinogen, D-dimer, von Willebrand factor, tissue factor, plasminogen activator inhibitor-1, tissue factor pathway inhibitor, tissue plasminogen activator, free thyroxine, hyperthyroidism
MeSH terms
Adult, Blood Coagulation, Female, Fibrinogen, Goiter, Humans, Prospective Studies, Thyroxine, Down-Regulation, Case-Control Studies, Thyroid Nodule, Plasminogen Activator Inhibitor 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review